Quick Answer
Galmed Pharmaceuticals Ltd. reported Total Revenue of $0.00 for fiscal year 2020.
Galmed Pharmaceuticals Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $0.00 |
| Net Income | -$10.31M -37.1% |
-$7.52M -8.8% |
-$6.91M +61.3% |
-$17.87M +45.0% |
-$32.47M -12.8% |
-$28.77M -40.6% |
| Diluted EPS | $2.39 -70.4% |
$8.08 -73.1% |
$30.00 -76.5% |
$127.80 +545.5% |
$19.80 | — |
| Total Assets | $18.63M +0.7% |
$18.50M +11.3% |
$16.63M +0.4% |
$16.56M -54.8% |
$36.60M -30.1% |
$52.38M -32.1% |
| Cash and Equivalents | $3.98M -14.3% |
$4.65M +62.6% |
$2.86M +41.9% |
$2.02M -30.1% |
$2.88M -58.5% |
$6.95M -56.4% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $15.78M -3.3% |
$16.33M +17.6% |
$13.88M +3.4% |
$13.42M -56.0% |
$30.50M -30.9% |
$44.15M -36.8% |
| R&D Expense | $4.87M +63.6% |
$2.98M -16.5% |
$3.57M -72.5% |
$12.99M -52.3% |
$27.22M +4.4% |
$26.08M +43.5% |
| Operating Income | — | — | — | — | — | -$30.21M -35.0% |
| Shares Outstanding | 6.58M +295.3% |
1.66M +190.2% |
573,741 -66.1% |
1.69M -93.3% |
25.09M +17.6% |
21.33M +0.9% |
- Galmed Pharmaceuticals Ltd. reported Total Revenue of $0.00 for fiscal year 2020.
- Galmed Pharmaceuticals Ltd. reported Net Income of -$10.31 million for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed a decrease of -37.1% in Net Income compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Diluted EPS of $2.39 per share for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed a decrease of -70.4% in Diluted EPS compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Total Assets of $18.63 million for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed an increase of +0.7% in Total Assets compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Cash and Equivalents of $3.98 million for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed a decrease of -14.3% in Cash and Equivalents compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Long-Term Debt of $0.00 for fiscal year 2017.
- Galmed Pharmaceuticals Ltd. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Stockholders Equity of $15.78 million for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed a decrease of -3.3% in Stockholders Equity compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported R&D Expense of $4.87 million for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed an increase of +63.6% in R&D Expense compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Operating Income of -$30.21 million for fiscal year 2020.
- Galmed Pharmaceuticals Ltd. showed a decrease of -35.0% in Operating Income compared to the prior fiscal year.
- Galmed Pharmaceuticals Ltd. reported Shares Outstanding of 6.58 million shares for fiscal year 2025.
- Galmed Pharmaceuticals Ltd. showed an increase of +295.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: